Equity Details
Price & Market Data
Price: $0.03
Daily Change: -$0.007 / 23.33%
Daily Range: $0.03 - $0.05
Market Cap: $336,317
Daily Volume: 245,903
Performance Metrics
1 Week: -34.90%
1 Month: -30.90%
3 Months: -36.84%
6 Months: -58.14%
1 Year: -78.82%
YTD: -45.45%
About Bio-Path Holdings, Inc. (BPTH)
An in-depth look at Bio-Path Holdings, Inc. (BPTH). Trading at 0.03, the stock shows a daily change of -$0.007 / 23.33%. Market cap: 336,317. Examine its 1-week, 3-month, and 1-year performance.
Company Details
Employees: 1
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.